Text and Data Mining valid from 2019-07-08
First Online: 8 July 2019
Compliance with Ethical Standards
: No external funding was used in the preparation of this manuscript.
: Nathan D. Wong, PhD, has received research support through the University of California, Irvine, from Amgen, Amarin, Novo Nordisk, and Boehringer Ingelheim; speaking fees from Amarin and Sanofi; and consulting fees from Amarin and Novartis. Peter Toth, MD, PhD, notes speaking fees from Amarin, Amgen, Kowa, Nova Nordisk, Regeneron, and Sanofi, and consultant/advisory board participation for Amarin, Amgen, Kowa, Nova Nordisk, Regeneron, and Sanofi. Christie Ballantyne, MD, has received speaking fees from Akcea, Amgen, Esperion, Novartis, Regeneron, and Sanofi-Synthelabo (all paid to institution, not individual), and consulting fees or honorarium from Akcea, Amarin, Amgen, Arrowhead, AstraZeneca, Boehringer Ingelheim, Esperion, Intercept, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, and Sanofi-Synthelabo. Ezra A. Amsterdam, MD, Amit Khera, MD, and Khurram Nasir, MD, MPH, declare no potential conflicts of interest that might be relevant to this article.